Seagen and Dai­ichi are duk­ing it out over the link­ers used in some block­buster drug plays. Could that af­fect a high-dol­lar As­traZeneca col­lab­o­ra­tion?

As­traZeneca and Dai­ichi Sankyo have struck gold as part of a high-dol­lar ADC col­lab­o­ra­tion, with En­her­tu well on its way to block­buster sales. But Dai­ichi’s erst­while re­search part­ner Seagen be­lieves it’s owed a cut of the prof­it — and that could be a prob­lem for As­traZeneca.

An­a­lysts are ex­pect­ing a de­ci­sion by the end of the year on an ar­bi­tra­tion dis­pute be­tween Seagen and Dai­ichi claim­ing three of Dai­ichi’s an­ti­body-drug con­ju­gates, in­clud­ing block­buster-to-be En­her­tu, use im­proved tech­nol­o­gy from a for­mer pact be­tween the two com­pa­nies and there­fore are part­ly owned by Seagen.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER